Salarius issued U.S. patent for next-gen targeted protein degraders

Salarius Pharmaceuticals announces that the U.S. Patent and Trademark Office, USPTO, has issued U.S. Patent No. 11,773,080, titled “Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same.” This patent covers the composition of matter for novel molecular glue degraders and expires in mid-2039. As reported on August 8, 2023, Salarius retained Canaccord Genuity, LLC to lead a comprehensive review of strategic alternatives focusing on maximizing shareholder value. While these efforts are ongoing, the company continues to support its current programs, as appropriate. David Arthur, President and CEO of Salarius, said, “We are delighted to continue building our TPD portfolio using our deuterium-enabled chiral switching platform to identify and develop new therapeutics. The granting of this patent, the 17th issued to Salarius in TPDs across six patent families, demonstrates the ability of the DECS platform to develop novel protein degraders.”